Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Antipsychotic drugs stop fatal viral infection in brain cells

19.11.2004


Generic antipsychotic drugs can protect brain cells from a virus that causes a fatal nervous system disorder, according to research conducted at Brown University and Case Western Reserve University.



The disorder, called progressive multifocal leukoencephalopathy or PML, affects hundreds of Americans with suppressed immune systems, including kidney transplant recipients, cancer patients undergoing chemotherapy and an estimated 4 percent of people with AIDS.

PML is caused by the JC virus, which destroys the cells that produce the fatty sheath that covers nerve cells. This causes dementia, vision loss, movement and speech impairment, paralysis and coma. The disorder is fast moving and fatal; Many patients die within four months after onset. PML is also on the rise. Due to the AIDS pandemic, incidence of the disorder rose 20-fold in the United States between 1979 and 1994, according to a study conducted by federal researchers.


But a team of scientists, led by Brown virologist Walter Atwood, has found that a handful of antipsychotic drugs can prevent brain cells from becoming infected by the JC virus. The drugs may prove to be an effective, ready-made therapy for PML prevention or treatment. Their results are published in the current issue of Science. "This is very promising," Atwood said. "These are generic drugs we can take off the shelf that may help a lot of people." "It is likely that there are many other drugs with none of the potential side effects of antipsychotic drugs that will also block infection," said co-author Bryan Roth, professor of biochemistry at the Case School of Medicine and director of the National Institute of Mental Health’s Psychoactive Drug Screening Program.

Atwood, an associate professor of medical science in the Department of Molecular Microbiology and Immunology at Brown, has studied the JC virus for more than a decade. The virus is common – anywhere from 70 to 80 percent of adults carry it in a latent form – and it infects certain types of glial cells, which support and protect neurons. It travels to the brain in people with severely weakened immune systems. But scientists didn’t know precisely how it infects those cells. Atwood knew that cellular entry depended on a particular protein, called clathrin, and began to test compounds that would block it.

Atwood tried chlorprozamine, a drug used to control psychotic symptoms such as hallucinations and delusions, and found that it worked. But chlorprozamine can cause serious side effects, such as lowered blood pressure, stiffness and tremors, so Atwood and his team tested seven similar drugs. They found that three others, most notably the antipsychotic clozapine, also prevented infection in human glial cells without troubling side effects.

By pinpointing drugs that block the JC virus, researchers uncovered how the virus operates in the body. The JC virus attaches itself to a receptor on the surface of glial cells, called 5HT2AR, which normally binds with serotonin, a compound that plays an important role in depression and anxiety. That receptor, or cellular "gate," opens and allows the virus to get inside cells.

To be sure that 5HT2AR was the cellular receptor for the virus, Atwood’s team conducted a novel experiment. They took a line of cancer cells that lack 5HT2AR and inserted the receptor gene. They found that these re-engineered cells were now susceptible to infection from the JC virus. Then researchers used the antipsychotic drugs to see if they blocked the virus. They did.

By understanding that the JC virus can be stopped with clozapine and comparable serotonin receptor blocking drugs, Atwood and Roth said new avenues for PML therapy are now open. The antihistamine cyproheptadine, for example, could have the same effect on the virus. "Cyproheptadine has very high affinity for 5-HT2A receptors and is not likely to have many of the side effects associated with drugs like clozapine and chlorpromazine," Roth said.

Atwood is establishing collaborations with several clinical neurology centers to determine whether compounds such as cyproheptadine will, in fact, help prevent or treat PML. Atwood’s team at Brown included Gwendolyn Elphick, a research associate in the Department of Molecular Microbiology and Immunology; William Querbes, Joslynn Jordan, Sylvia Eash and Aisling Dugan, students in the graduate program in pathobiology; and Gretchen Gee, Kate Manley and Megan Stanifer, students in the graduate program in molecular biology, cell biology and biochemistry. Bryan Roth, Anushree Bhatnagar, and Wesley Kroeze from Case Western Reserve University Medical School collaborated with Atwood on the project.

Wendy Lawton | EurekAlert!
Further information:
http://www.brown.edu

More articles from Health and Medicine:

nachricht World first: Massive thrombosis removed during early pregnancy
20.07.2017 | Universitätsspital Bern

nachricht Therapy of preterm birth in sight?
19.07.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

Im Focus: Laser-cooled ions contribute to better understanding of friction

Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision

Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

NASA looks to solar eclipse to help understand Earth's energy system

21.07.2017 | Earth Sciences

Stanford researchers develop a new type of soft, growing robot

21.07.2017 | Power and Electrical Engineering

Vortex photons from electrons in circular motion

21.07.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>